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Abstract
Background: Understanding the role of alternative complement pathway dysregulation in membranoproliferative
glomerulonephritis (MPGN) has led to a dramatic shift in its classification into two subgroups: immune complex-
mediated MPGN and complement-mediated MPGN, consisting of dense deposit disease and C3 glomerulonephritis
(C3GN). A limited number of C3GN cases have been published to date with not yet conclusive results since the
novel therapeutic approach with eculizumab was introduced.
Case presentation: We report the clinical follow-up of a 16-year-old patient in whom a diagnosis of C3GN was
confirmed by immunofluorescence and electron microscopy in second and third kidney biopsies, while the first
biopsy revealed idiopathic immune complex-mediated MPGN type III, Anders and Strife variant, which failed to
improve after several attempts at conventional immunosuppression therapy. Although applied late in an already
fairly advanced stage of the severe active form of MPGN, the efficacy of eculizumab on C3GN was evidenced
clinically and pathohistologically. Its beneficial influence on pathomorphogenesis was demonstrated by a unique
follow-up in the last three biopsies, despite the recent observation, confirmed in this study, of eculizumab binding
within the kidney tissue.
Conclusions: Clinicians and pathologists should be aware that, in some patients, an underlying genetic or acquired
complement alternative pathway abnormality can be masked by an initial immune complex-mediated mechanism,
which subsequently triggers an unbalanced excessive continual driving of complement terminal pathway activation
and the development of C3GN. In such a patient, supplementary steroids in addition to eculizumab appear
necessary to achieve an adequate response.
Keywords: C3 glomerulonephritis, Eculizumab, Membranoproliferative glomerulonephritis, Complement alternative
pathway dysregulation
Background
Membranoproliferative glomerulonephritis (MPGN) shows
a distinct histopathological pattern of glomerular injury
but has many potential causes. Recent elucidation of the
possible pathogenesis of MPGN had led to its new classifi-
cation, into immune complex-mediated and complement-
mediated diseases [1, 2]. The first is driven by classical
complement pathway activation, while the second is
believed to be associated with complement alternative
pathway (AP) dysregulation and is a new entity, C3
glomerulopathy [3]. The latter embraces dense deposit dis-
ease (DDD) and examples of MPGN type I and III in
which immunofluorescence reveals exclusive or predomin-
ant C3 deposits, now termed C3 glomerulonephritis
(C3GN) [1–7].
Predominant C3 deposits detected by immunofluores-
cence define C3 glomerulopathy but its original definition
as “C3 only” appeared too stringent if the goal of the
diagnosis is to identify all candidates for evaluation of com-
plement AP dysregulation. A new definition of C3 glomeru-
lopathy was therefore proposed when C3 dominance is at
least two orders of magnitude stronger than any other
immune reactant [4, 8]. C3GN comprises in addition to
MPGN also other histomorphologic patterns [4].
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We describe a clinical case of a 16 year-old boy with
C3GN, mediated by complement AP dysregulation,
which appeared to be triggered by immune complex-
mediated MPGN. He was successfully treated with eculi-
zumab after conventional immunosuppression failed to
result in clinical and laboratory improvement, but the
immune complexes had disappeared in the second kid-
ney biopsy, redefining the renal disease as C3GN.
Case presentation
Clinical history and initial laboratory data
A previously healthy boy presented at the age of 16 with
edema, headache and paleness. He was hypertensive (RR
164/110 mmHg), with no other abnormalities on phy-
sical examination.
Nephrotic syndrome was confirmed (edema, proteinuria
4 - 18 g/day, hypoalbuminemia 21 – 28 g/L, typically
changed proteinogram and lipidogram) with some ad-
ditional elements of nephritic syndrome (microhematuria,
hypertension). He was anemic but had normal platelets.
LDH was normal at that time (4.1 mckat/L) but rose to
twice as much very shortly afterwards. Serum creatinine
was normal at disease presentation (73 μmol/L), as were
liver tests and coagulation. He had ascites, enlarged and
hyperechogenic kidneys and left ventricular hypertrophy.
Follow-up values of laboratory parameters in relation to
therapeutic approaches are given in Table 1.
Kidney biopsies, diagnosis and clinical follow-up
The first kidney biopsy, ten days after initial clinical pres-
entation, showed immune complex-mediated MPGN, clas-
sified as type III, Anders and Strife variant. Detailed
findings of light microscopy, immunofluorescence and
electron microscopy findings are given in Table 2, inclu-
ding five consecutive kidney biopsies, while representative
pictures are presented in Figs. 1 and 2.
We found low activity of alternative and classical com-
plement pathways, low C3 and normal C4, CFH, CFI and
CFB. C3 nephritic factor (5 %; ref.: <10 %) and anti-CFH
antibodies (46 AU/ml; ref.: <110 AU/ml) were negative.
Anti-C1q antibodies (93 IU/ml; ref. <15 IU/ml) were posi-
tive, while all other laboratory examinations for possible
autoimmune disease were negative. Cryoglobulinemia,
paraproteinemia and chronic infections were ruled out.
The boy was initially treated for suspected lupus neph-
ritis, although he never fulfilled ARA criteria for sys-
temic lupus erythematosus. The detailed treatment is
described in Table 1. Despite all conventional immuno-
suppressive therapeutic approaches, the boy remained
heavily nephrotic, with persistent malignant hyperten-
sion (RR 180 – 190/100 – 110 mmHg) on 7 antihyper-
tensive drugs, severe dyslipidemia and slowly increasing
s-creatinine. One month after the last dose of rituximab,
with no clinical and laboratory improvement, a second
kidney biopsy was performed. It showed decreased IgG but
persisting bright C3 staining, thus fulfilling the diagnostic
criteria for C3GN and changing the pathohistological diag-
nosis from immune complex-mediated to complement-
mediated MPGN III (Table 2, Figs. 1 and 2). This was even
more evident in the third biopsy, in which IgG deposition
had disappeared entirely, while C3 remained unchanged.
Before starting eculizumab, one year after the first clinical
symptoms, severe glomerular inflammatory activity with
nearly 70 % of mostly active cellular and fibrocellular cres-
cents was already associated with 46 % of mostly segmental
glomerulosclerosis and 70 % of interstitial fibrosis (Table 2,
Figs. 1 and 2). The patient was still heavily nephrotic. Low
serum C3 values associated with extremely high (6615
mcg/L) serum membrane attack complex (sMAC) sug-
gested that dysregulation of complement AP was respon-
sible for the ongoing nephrotic syndrome. The patient was
therefore put on eculizumab after the third biopsy. In
addition to completely normalized sMAC (263 mcg/L)
after two months of treatment, associated continuing
improvement of renal function and proteinuria was
evident (Table 1). After initiation of eculizumab, the
fourth renal biopsy revealed a significant decrease of
glomerular inflammatory activity (complete disappear-
ance of glomerular infiltration by neutrophils and
necrotizing lesions, significantly reduced glomerular
proliferation rate), the latter being sustained throughout
the treatment, as demonstrated by the fifth and six renal
biopsies (Tables 1, 2, Figs. 1 and 2). Furthermore, newly
developed cellular crescents were no longer found and a
gradual decrease or switching of fibrocellular to com-
pletely inactive fibrous crescents, associated with partial
replacement of segmental with global glomerulosclerosis,
was observed in follow-up biopsies after eculizumab was
introduced.
In the fourth biopsy, we noticed de novo staining for
IgG2, IgG4, kappa and traces of IgG1, IgG3 reappeared in
association with gradually worsening proteinuria, while the
patient was off all conventional immunosuppression drugs.
A fifth biopsy was performed, showing intensified IgG1,
IgG3 staining and persisting staining for monoclonal IgG2,
IgG4, kappa (Table 2, Fig. 2). Reintroducing conventional
immunosuppression with steroids, in addition to eculizu-
mab, resulted in clinical and laboratory improvement,
which is still being sustained. The final kidney biopsy
showed persistently suppressed glomerular inflammatory
activity, slightly increased glomerulosclerosis and a de-
crease of IgG1, IgG3 deposits, while monoclonal IgG2,
IgG4, kappa remained virtually unchanged and C3 deposits
remained of the same intensity in all 6 biopsies, even when
eculizumab was introduced (Table 2, Fig. 2). While exten-
sive interstitial fibrosis, already present before introducing
eculizumab, persisted at a similar rate, a gradually increas-
ing intensity of interstitial inflammation was observed,
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Table 1 Laboratory parameters in relation to treatment modalities
Legend for normal values:
s-creatinine 44 – 97 mcmol/L; s-albumin 32 – 55 g/L; u-24 h-protein <0,25 g/day; CH50 – total hemolytic classical complement pathway 72 – 128 %; AP50 – total
hemolytic alternative complement pathway 80 – 120 E; C3 – C3 complement factor 920 – 1576 mg/L; C4 – C4 complement factor 162 – 445 mg/L; uMAC –
complement lytic complex in urine <30 mcg/L; sMAC – complement lytic complex in serum 300 – 350 mcg/L
Legend to the treatment:
Methylprednisolone 3x pulse 10 mg/kg/day i.v. (Aug 12, 13, 14, 2011)
Methylprednisolone 1 mg/kg/day p.o. (Aug 15 – Sep 22, 2011), thereafter slowly tapering dose
Mofetil mycophenolate 2 x 1000 mg/day p.o. (Sep 10 – Dec 22, 2011)
Resochine 1 tbl/day p.o. (Sep 20, 2011 – Sep 6, 2012)
Tacrolimus kept at a desired level 5 – 7 mcg/L p.o. (Nov 22, 2011 – Jan 5, 2012)
Rituximab 2 x 875 mg i.v. (Feb 3, 2012 and Feb 17, 2012)
Cyclophosphamide 1000 mg i.v. (Apr 2, 2012) + 750 mg i.v. (Apr 30, 2012)
Methylprednosolone 6x pulse 1 g i.v. (Apr 4, 5, 6, 7, 8, 9, 2012)
Methylprednisolone 0,5 mg/kg/day p.o. (Apr 10 – May 15, 2012), thereafter slowly tapering dose)
Plasmapheresis with fresh frozen plasma 32 sessions (May 3 – Aug 9, 2012)
Eculizumab 900 mg/week 3-times, thereafter 1200 mg/2 weeks; ongoing (Aug 16, 2012)
Methylprednosolone 3x pulse (Feb 24, 25, 26, 2014)
Methylprednisolone 1 mg/kg/day p.o. (Feb 27 – Apr 3, 2014), thereafter slowly tapering dose, kept at 8 mg/2nd day
Mofetil mycophenolate 2 x 1000 mg/day p.o. (Apr 3, 2014 - ongoing)
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Table 2 Light microscopy, immunofluorescence and electron microscopy results of six successive renal biopsies in relation to
treatment modalities
Legend: % – proportion of glomeruli with lesion and estimated semi-quantitative tubulo-interstitial involvement, respectively; intensity – semi-quantitative values
0-3+; crescents active – cellular and fibrocellular; crescents inactive – fibrous; eculizumab treatment from August 16, 2012 ongoing
Abbreviations: G glomerular, T-I tubulo-interstitial, V vascular, cel cellular, fibrocel fibrocellular, fibro fibrous, GS glomerulosclerosis, seg segmental, glob global, dps deposits
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Fig. 1 (See legend on next page.)
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accompanied by tubular lipidosis and cholesterol crystal-
line deposits, as well as partial switching of segmental to
global glomerulosclerosis (Table 2, Fig. 1).
Molecular genetic analysis showed no evidence of
disease-causing mutations in the genes coding for C3,
CD46, CFB, CFH, CFHR1, CFHR2, CFHR3, CFHR4,
CFHR5, CFI and THBD but the patient was found to
be heterozygous for four CFH single nucleotide poly-
morphisms. These polymorphisms included exon 9
c.1204C > T p.H402Y (CAT > TAT), as well as exon 7
c.921A > C p.A307A (GCA > GCC), exon 13 c.2016A >
G p.Q672Q (CAA > CAG) and exon 18 c.2808G > T
p.E936D (GAG > GAT).
Discussion
A clinical case of a 16-year-old boy with presumed com-
bined immune complex-mediated and complement-
mediated MPGN is described. At the first renal biopsy,
immune complex-mediated MPGN, classified as type III,
variant Anders and Strife, was found associated with
dominant 3+ staining for C3 and 2+ staining for IgG,
subclasses IgG1 and IgG3. According to the definition of
C3GN, characterized by C3 dominance of at least two
orders of magnitude of intensity more than any other
immune reactant [4, 8], these findings did not fulfill the
criteria for C3GN. After multiple conventional immuno-
suppression approaches applied to the patient, while
bright C3 staining persisted, IgG diminished and finally
disappeared, which gave a diagnosis of C3GN in the sec-
ond and following biopsies. It has already been proposed
that, in some patients, MPGN is initiated by immune
complexes but the disease is accelerated by complement
AP dysregulation [5, 9]. It can be hypothesized that acti-
vation of the complement classical pathway, initiated by
immune complex deposition, might through the release
of C3b, a constituent of AP C3bBb convertase, have
augmented and perpetuated the activation of dysregu-
lated complement AP. Although it has been described
that patients with C3GN might suffer from mutation in
one or more of the complement genes or produce auto-
antibodies against the complement regulatory proteins
and/or AP C3 convertase [2–4, 10, 11], we could not find
any disease-causing mutation, nor auto-antibodies associ-
ated with complement AP dysregulation in our patient.
We did however find polymorphism in the CFH gene,
which has already been described in some patients with
DDD [12], as well as CFH polymorphisms evidenced in pa-
tients with atypical hemolytic uremic syndrome [13, 14].
There are 11 reported cases on the use of eculizumab
for treatment of C3GN, mostly but not always with good
results [15–25]: 7 cases in native kidneys and 4 as a re-
currence in transplant kidneys. Of the 7 cases, one was
immune complex MPGN type I, refractory to conven-
tional immunosuppression, with complement analysis
strongly suggesting AP activation, positive C3 nephritic
factor and several polymorphisms in complement regu-
lators on genetic testing but without re-biopsy after ecu-
lizumab [15]. Furthermore, Kerns et al. [20] described a
similar patient to ours in whom the initial kidney biopsy
revealed immune complex-mediated MPGN, although
without detailed subtyping, and in whom standard im-
munosuppression resulted in histologic transformation
into C3GN, but without biopsy follow-up after eculizu-
mab treatment. Our patient had a much longer clinical
and histological follow-up, with six successive kidney bi-
opsies, the last three after eculizumab had been intro-
duced. It has been suggested that MPGN III of Anders
and Strife, identified in our case, often represents C3GN
[4]. In addition, it must be noted that complement AP
abnormalities, genetic or acquired, have been identified
in a subset of patients showing susceptibility to systemic
lupus erythematosus [5], and particularly frequently in
(See figure on previous page.)
Fig. 1 Light and electron microscopic images of 6 successive renal biopsies compared with various therapies. (1A-C) Initial biopsy with immune
complex immunofluorescence pattern showing severe glomerular endocapillary proliferation and leukocyte exudation (a – H&E), glomerular
basement membrane double contours (b – methenamine silver), prevailing transmembranous and scattered hump-shaped deposits (C – electron
micrograph). (2A-C) On conventional immunosuppressive therapy in the second biopsy with highly dominant C3 immunofluorescence, severe
glomerular proliferation, leukocyte exudation with pronounced lobularity (a – H&E), extensive capillary wall mesangial interposition with glomerular
basement membrane double contours and disruption (b – methenamine silver), evidenced also on electron micrograph (c). (3A-C) On rituximab and
plasmapheresis in the third biopsy, only slightly less active C3 membranoproliferative glomerulonephritis type III of Anders and Strife but significantly
increased interstitial fibrosis with tubular fatty degeneration and cholesterol crystalline clefts, fibrocellular crescents and glomerulosclerosis (a – H&E,
B – methenamine silver, c – electron micrograph). (4A-C) After initiation of eculizumab, while interstitial fibrosis, focal segmental glomerulosclerosis
(a – AFOG trichrome) and mesangial-transmembranous deposits persist, a significant decrease in glomerular hypercellularity, active crescents and
disappearance of leukocyte infiltration and necrotizing lesions are visible on methenamine silver stained section (b) and electron micrograph (c). (5A-B)
With ongoing eculizumab therapy but withdrawal of conventional immunosuppression associated with the reappearance of immune complex
immunofluorescence, similar histopathology as in the fourth biopsy (a – AFOG trichrome) but more pronounced refractile red stained glomerular
capillary wall and mesangial deposits share some similarities to those of dense deposit disease (b – AFOG trichrome) and on the inner aspect of
transmembranous deposits interrupting powdery dense deposits ascribed to eculizumab binding are visible on electron micrograph (c). (6A-C) After
ongoing eculizumab and methyprednisolone therapy, chronic C3 glomerulonephritis presents similarly as in the fifth biopsy, with significant focal
segmental glomerulosclerosis and interstitial fibrosis (a – AFOG trichrome), a lower level of glomerular proliferation and absence of active glomerular
inflammation (b – AFOG trichrome) but with continuous powdery electron dense deposits (c – electron micrograph)
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Fig. 2 (See legend on next page.)
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patients with immune complex-mediated MPGN [26]
and atypical post-infectious glomerulonephritis [27], the
latter showing overlapping features with C3GN [28].
Since eculizumab is a humanized monoclonal antibody
that binds with high affinity to C5 and prevents the gen-
eration of MAC and release of the very potent inflam-
matory mediator C5a, it may provide effective targeted
treatment for patients with C3GN sharing in common
an abnormality in the regulation of complement AP
[29]. However, it has been suggested that eculizumab
might be effective in some but not all cases of C3GN,
and that elevation of sMAC, short disease duration,
acute lesions and limited fibrosis before treatment may
predict a favorable response [2, 4, 22]. The benefit of
eculizumab was confirmed in our patient not only with
complete normalization of previously highly increased
sMAC but also with improvement of the clinical features
and laboratory findings. Furthermore, a significant low-
ering of glomerular inflammatory activity was demon-
strated in the last three follow-up biopsies by the
disappearance of neutrophil infiltration and necrotizing
lesions, switching of active to inactive fibrous crescents
and a decrease in glomerular proliferation intensity. Glo-
merulosclerosis only slightly increased, associated with a
gradual partial replacement of a segmental with a global
type of this scarring lesion, probably related to some ex-
tent also to non-immune factors, particularly arterial
hypertension. Extensive interstitial fibrosis had mostly
been established before eculizumab was introduced.
Tubular fatty degeneration and cholesterol crystalline
clefts can be ascribed to severe hyperlipidemia. Further-
more, interstitial inflammation is presumably also unre-
lated to basic complement AP dysregulation but caused
by other secondary mechanisms in chronic glomerular
diseases.
As in the presented case, the literature shows that pre-
scription of eculizumab in C3GN is frequently delayed
until alternative diagnostic possibilities have been ruled
out and conventional immunosuppressive approaches
have failed [30]. The question arises of when it is too late
to initiate such expensive and potentially long-term
treatment. Clinical and biopsy follow-up in our patient
convincingly demonstrated that, although delayed, insti-
tution of eculizumab therapy to a patient with already
fairly advanced active C3GN, with nearly 70 % of mostly
active crescents, resulted not only in clinical improve-
ment but also in a persistent significant decrease in
glomerular inflammatory activity and cessation of fur-
ther progression of renal disease, as shown in the last
three follow-up biopsies. Our observation is in line with
reports of recovery of renal function and decrease of
proteinuria rate in one patient with crescentic, clinically
rapidly progressive GN [24] and in another similar pa-
tient already on dialysis, which could be discontinued
after 5 months of eculizumab therapy [25]. It appears
that, in such cases, a minimum of six months of eculizu-
mab application might be necessary prior to declaring
treatment failure [25, 30]. However, it has to be consid-
ered that case reports might be biased by selective
reporting of positive results. Non-selective case reports
of the rare disease and, especially, randomized prospect-
ive controlled studies are expected to provide accurate
results about the efficacy of eculizumab in C3GN.
It has already been reported that in biopsies performed
after eculizumab treatment, there was de novo staining
for monoclonal IgG2, IgG4, kappa with the same distri-
bution as C3 and C5b-9, suggesting the binding of the
humanized monoclonal antibody eculizumab onto pre-
existing complement deposits in the renal tissue [18]. At
the same time, there was a marked decrease in inflam-
matory activity observed post-treatment although stain-
ing for C3 and C5b-9 appeared largely unchanged in the
pre-treatment and post-treatment biopsies [18]. Similar
results were obtained in our patient in post-treatment
biopsies, with de novo staining for monoclonal IgG2,
IgG4, kappa and persistent unchanged staining for C3.
Furthermore, the results of Herlitz et al. [18] after one
year of therapy were confirmed in our study in all three
of the last biopsies during a two-year follow up, without
convincing evidence of any harmful influence of eculizu-
mab tissue binding. However, the long-term clinical
significance of this drug-tissue interaction still remains
unclear. Long-term eculizumab use has been studied in
patients with paroxysmal nocturnal hemoglobinuria and
there was no evidence of the development of proteinuria
or renal insufficiency [31]. The transitory worsening of
the clinical picture and reappearance of IgG1 and IgG3
in kidney biopsy samples after several months of initially
(See figure on previous page.)
Fig. 2 Immunofluorescence microscopic images of six successive renal biopsies compared with various therapies. (First biopsy) Granular glomerular
mesangial and particularly capillary wall immunofluorescence moderate staining for IgG, subclass IgG3 and intense bright staining for C3. (Second biopsy)
Scanty segmental glomerular granular staining for IgG, subclass IgG3, and intense staining for C3. (Third biopsy) Negative immunofluorescence for IgG,
subclass IgG3, and pattern and intensity of C3 as in previous two biopsies. (Fourth biopsy) After introduction of eculizumab therapy immunofluorescence
showing moderate granular mesangial and capillary wall as well as extraglomerular vessel and extensive tubular staining for IgG2, IgG4, kappa. (Fifth
biopsy) On persisting eculizumab therapy but withdrawal of conventional immunosuppression reappearance of immune complex pattern expressed as
segmental granular staining for IgG1, while moderate granular glomerular, extraglomerular vascular and tubular staining for IgG4 and intense bright
staining for C3 persist. (Sixth biopsy) After ongoing eculizumab and methyprednisolone therapy immunofluorescence showing only segmental scanty
granular staining for IgG3, persisting glomerular and extraglomerular staining for IgG4 and still intense staining for C3
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successful treatment with eculizumab in our patient can
be explained by recurrence of the immune complex-
mediated mechanism following the complete withdrawal
of conventional immunosuppression. This is supported
by the patient’s clinical and histomorphological improve-
ment after methylprednisolone was reintroduced.
Conclusions
We describe a patient with C3GN due to complement AP
dysregulation, triggered by immune complex-mediated
MPGN III, variant Anders and Strife, who was successfully
treated with eculizumab after treatment failure with various
conventional immunosuppression approaches. His clinical
condition, however, deteriorated temporarily after several
months of eculizumab treatment, probably due to the un-
suppressed immune complex-mediated mechanism of his
disease, identified by the reappearance of IgG deposits in
biopsies when the patient was temporarily completely off
all conventional immunosuppression drugs. It must be
stressed that in primary immune complex-mediated glom-
erulonephritis, especially MPGN, which does not respond
to immunosuppression, the presence of complement AP
dysregulation should be considered. In such a case, special
laboratory and molecular genetic tests must be done to ex-
plore the exact pathophysiology of the disease and target
the treatment accordingly. Furthermore, our significantly
longer biopsy follow-up study confirms the recent new ob-
servation of eculizumab binding to renal tissue without ap-
parent evidence of its injurious consequences, although
eculizumab deposits share some similarities with those of
monoclonal immunoglobulin deposit diseases.
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